Contineum Therapeutics, Inc.
Q2 2024 13F Holders
Symbol
CTNM
CUSIP
21217B100
Type
Equity
Class
CL A
Num filings
52
Total reported value, excl. options
$229 M
Compare 2024 Q2 to
2025 Q1
2024 Q4
2024 Q3
Manager
Report Date
Value ($000)
Shares
Option Type